Susquehanna International Group
NRXP icon

Susquehanna International Group’s NRX Pharmaceuticals NRXP Stock Holding History

Susquehanna International Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-82,152
Closed -$231K – 13143
2024
Q4 		$181K Buy
+82,152
New +$110K ﹤0.01% 10838
2023
Q4 		– Sell
-1,410
Closed -$4.66K – 12999
2023
Q3 		$3.67K Buy
+1,410
New +$4.69K ﹤0.01% 11813
2023
Q2 		– Sell
-8,062
Closed -$48.5K – 12801
2023
Q1 		$53.1K Buy
8,062
+5,289
+191% +$53.6K ﹤0.01% 11677
2022
Q4 		$30.8K Sell
2,773
-1,536
-36% -$15.5K ﹤0.01% 11615
2022
Q3 		$32K Sell
4,309
-4,448
-51% -$30K ﹤0.01% 12424
2022
Q2 		$53K Buy
8,757
+5,696
+186% +$74.8K ﹤0.01% 11948
2022
Q1 		$75K Sell
3,061
-4,835
-61% -$157K ﹤0.01% 12091
2021
Q4 		$377K Buy
7,896
+2,363
+43% +$171K ﹤0.01% 9931
2021
Q3 		$513K Buy
+5,533
New +$720K ﹤0.01% 9339
2019
Q3 		– Sell
-1,147
Closed -$120K – 10622
2019
Q2 		$120K Buy
+1,147
New +$119K ﹤0.01% 9519

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group's NRXP Position: Q1 2025 in Review

Susquehanna International Group sold out of NRX Pharmaceuticals (NRXP) in Q1 2025, closing a stake of 82,152 shares — an estimated $231K sold.

Susquehanna International Group first reported a position in NRXP in Q2 2019 and held it in 10 quarters. The position peaked at $513K in Q3 2021. 22 funds tracked by Wall St. Rank hold NRXP as of Q1 2025.

  • Susquehanna International Group reported no remaining NRX Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 82,152 NRX Pharmaceuticals shares in Q1 2025, an estimated $231K.
  • Susquehanna International Group first reported a position in NRX Pharmaceuticals in Q2 2019 and held it in 10 quarters.
  • Susquehanna International Group's NRX Pharmaceuticals position peaked at $513K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.